Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: A possible marker for the disease's subtypes

Psychiatry Research

Volumn 127, Issue 3, 2004, Pages 227-235

  Segal, Michael ^a   Avital, Avi ^b   Rojas, Marina ^a   Hausvater, Noemi ^a   Sandbank, Sergio ^a   Liba, David ^a   Moguillansky, Leonardo ^a   Tal, Ilana ^a   Weizman, Abraham ^c,d  

^a Flugelman's Mental Hlth Med Ctr   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Disorganized; Dopamine; Paranoid; Prolactin; Schizoaffective

Indexed keywords

MARKER; PROLACTIN;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOPAMINERGIC ACTIVITY; FEMALE; HEBEPHRENIA; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHIATRIST; RATING SCALE; RECURRENT DISEASE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ADULT; BIOLOGICAL MARKERS; DOPAMINE; FEMALE; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; MIDDLE AGED; PATIENT ADMISSION; PROLACTIN; RECURRENCE; SCHIZOPHRENIA;

EID: 3543100350     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2004.01.010     Document Type: Article

References (53)

1. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., Weiss R., Cooper T.B., Mann J.J., Van Heertum R.L., Gorman J.M., Laruelle M. From the cover: increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 97:2000;8104-8109
2. Abi-Dargham A. Recent evidence for dopamine abnormalities in schizophrenia. European Psychiatry. 17:(Supplement 4):2002;341-347
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed:1994;Author, Washington, DC
4. Andreasen N.C., Olsen S.A. Negative vs. positive schizophrenia: definition and validation. Archives of General Psychiatry. 39:1982;789-794
5. Angelopoulos E.K., Markianos M., Daskalopoulou E.G., Hatzimanolis J., Tzemos J. Changes in central serotonergic function as a correlate of duration of illness in paranoid schizophrenia. Psychiatry Research. 15:(110):2002;9-17
6. Angrist B., van Kammen D.P. CNS stimulants as a tool in the study of schizophrenia. Trends in Neuroscience. 7:1984;388-390
7. Angrist B., Peselow E., Rubinstein M., Wolkin A., Rotrosen J. Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology. 85:1985;277-283
8. Appelberg B., Katila H., Rimon R. Inverse correlation between hallucinations and serum prolactin in patients with non-affective psychoses. Schizophrenia Research. 44:2000;183-186
9. Carlsson A., Lindquist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologica and Toxicologica. 20:1963;140-144
10. Carlsson A. Antipsychotic drugs, neurotransmitters and schizophrenia. American Journal of Psychiatry. 135:1978;164-173
11. Chou J.C., Douyon R., Czobor P., Volavka J., Cooper T.B. Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Research. 81:1998;51-55
12. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 19:1976;481-483
13. Crow T.J. Two dimensions of pathology in schizophrenia: dopaminergic and non-dopaminergic. Psychopharmacology Bulletin. 18:1982;22-29
14. Csernansky J.G., Prosser E., Kaplan J., Mahler E., Berger P.A., Hollister L.E. Possible associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated male schizophrenics. Biological Psychiatry. 7:1986;632-642
15. Davis B.M., Davis K.L., Mohs R.C., Mathé A.A., Rothpearl A.B., Johns C.A., Levy M.I., Horvath T.B. Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems. Archives of General Psychiatry. 42:1985;259-264
16. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. American Journal of Psychiatry. 148:(11):1991;1474-1486
17. Davidson M., Keefe R.S., Mohs R.C., Siever L.J., Losonczy M.F., Horvath T.B., Davis K.L. L-Dopa challenge and relapse in schizophrenia. American Journal of Psychiatry. 144:1987;934-938
18. Ellinwood E.H. Jr, Sudilovsky A., Nelson L.M. Evolving behavior in the clinical and experimental amphetamine (model) psychosis. American Journal of Psychiatry. 130:1973;1088-1093
19. Faraone S.V., Brown W.A., Laughren T.P. Serum neuroleptic levels, prolactin levels, and relapse: a 2-year study of schizophrenic outpatients. Journal of Clinical Psychiatry. 48:1987;151-154
20. Farde L., Wiesel F.A., Halldin C., Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Archives of General Psychiatry. 45:1988;71-76
21. Fenton W.S., McGlashan T.H. Natural history of schizophrenia subtypes. I. Longitudinal study of paranoid, hebephrenic and undifferentiated schizophrenia. Archives of General Psychiatry. 48:1991;969-977
22. Finlay J.M. Mesoprefrontal dopamine neurons and schizophrenia: role of developmental abnormalities. Schizophrenia Bulletin. 27:2001;431-442
23. Glazer W.M., Bowers M.B. Jr, Charney D.S., Heninger G.R. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia. Biological Psychiatry. 26:1989;224-233
24. Grace A.A. Phasic vs. tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 4:1991;1-24
25. Green A.I., Faraone S.V., Brown W.A. Prolactin shifts after neuroleptic withdrawal. Psychiatry Research. 32:1990;213-219
26. IMx Prolactin assay. Abott Laboratories, 1997. Diagnostic Division: 1-11
27. Kaneda Y., Fujii A. Effects of chronic neuroleptic administration on the hypothalamo-pituitary-gonadal axis of male schizophrenics. Progress in Neuropsychopharmacology and Biological Psychiatry. 24:2000;251-258
28. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry. 157:2000;514-520
29. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry. 160:2003;13-23
30. Kay S., Fiszbein A., Opler L. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 13:1987;261-276
31. Keks N.A., Copolov D.L., McKenzie D.P., Kulkarni J., Hill C., Hope J.D., Singh B.S. Basal and haloperidol-stimulated prolactin and symptoms of non-affective and affective psychoses in neuroleptic-free men. Biological Psychiatry. 37:1995;229-234
32. Kirkpatrick B., Carpenter W.T., Maeda K., Buchanan R.W., Breier A., Tamminga C.A. Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients. Biological Psychiatry. 32:1992;1049-1054
33. Kirch D.G., Jaskiw G., Linnoila M., Weinberger D.R., Wyatt R.J. Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients. Psychiatry Research. 25:1988;233-242
34. Knable M.B., Egan M.F., Gorey H.J., Lee K.S., Coppola R., Weinberger D.R. Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia. British Journal of Psychiatry. 171:1997;574-577
35. Knoll I.V., Garver D.L., Ramberg J.E., Kingsbury S.J., Croissant D., McDermott B. Heterogeneity of the psychoses: is there a neurodegenerative psychosis? Schizophrenia Bulletin. 24:1998;365-369
36. Laruelle M., Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. Journal of Psychopharmacology. 13:1999;358-371
37. Lieberman J.A., Kane J.M., Gadaleta D., Brenner R., Lesser M.S., Kinon B. Methylphenidate challenge as a predictor of relapse in schizophrenia. American Journal of Psychiatry. 141:1984;633-638
38. Lieberman J.A., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 91:1987;415-433
39. Magaro P., Abrams L., Canrell P. The Maine Scale of Paranoid and Non-paranoid Schizophrenia: reliability and validity. Journal of Consulting and Clinical Psychology. 49:1981;438-447
40. Melkersson K.I., Hulting A.L., Rane A.J. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. British Journal of Clinical Pharmacology. 51:2001;317-324
41. Meltzer H.Y., Sachar E.J., Frantz A.G. Serum prolactin levels in unmedicated schizophrenic patients. Archives of General Psychiatry. 31:1974;564-569
42. Meltzer H.Y., Fang V.S. The effect of neuroleptics on serum prolactin in schizophrenic patients. Archives of General Psychiatry. 33:1976;279-286
43. Nordström A.L., Farde L. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. Journal of Clinical Psychopharmacology. 18:1998;305-310
44. Oades R.D., Klimke A., Henning U., Rao M.L. Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia. Human Psychopharmacology. 17:2002;15-27
45. Otani K., Kondo T., Ishida M., Tanaka O., Yasui N., Suzuki A., Kaneko S. Plasma prolactin concentration and psychopathology of schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry. 20:1996;1369-1374
46. Peralta V., de Leon J., Cuesta M.J. Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy. British Journal of Psychiatry. 161:1992;335-343
47. Rubin R.T. Prolactin and schizophrenia. Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. 1987;803-808 Raven Press, New York
48. Stevens J.R. Schizophrenia: reproductive hormones and the brain. American Journal of Psychiatry. 159:2002;713-719
49. van Kammen D.P., Docherty J.P., Bunney W.E. Jr. Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment. Biological Psychiatry. 17:1982;233-242
50. Van Putten T., Marder S.R., Mintz J. Serum prolactin as a correlate of clinical response to haloperidol. Journal of Clinical Psychopharmacology. 11:1991;357-361
51. Warner M.D., Walker A.M., D'Souza D.C., Lee D., Nasseri D., Peabody C.A. Lower prolactin bioactivity in unmedicated schizophrenic patients. Psychiatry Research. 102:2001;249-254
52. Wolkin A., Sanfilipo M., Duncan E., Angrist B., Wolf A.P., Cooper T.B., Brodie J.D., Laska E., Rotrosen J.P. Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms. American Journal of Psychiatry. 153:1996;346-354
53. Zhang X.Y., Zhou D.F., Yuan C.L., Zhang P.Y., Wu G.Y., Shen Y.C. Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. Psychiatry Research. 109:2002;297-302